<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Membrane-bound <z:chebi fb="0" ids="16247">phospholipid</z:chebi> scramblase 1 (PLSCR1) is involved in both <z:chebi fb="23" ids="18059">lipid</z:chebi> trafficking and cell signaling </plain></SENT>
<SENT sid="1" pm="."><plain>Previously, we showed that PLSCR1 is overexpressed in many colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study, we investigated the tumorigenic role of PLSCR1 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and suggest that it is a potential therapeutic target </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: To identify PLSCR1 as a therapeutic target, we studied the tumorigenic properties of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines treated with a monoclonal antibody (NP1) against the N-terminus of PLSCR1 in vitro and in vivo </plain></SENT>
<SENT sid="4" pm="."><plain>We also investigated cell cycle status and epidermal growth factor receptor-related pathways and downstream effectors of PLSCR1 after blocking its function with NP1 </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Treating <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells with NP1 in vitro and in vivo <z:mp ids='MP_0000352'>decreased cell proliferation</z:mp>, anchorage-independent growth, migration, and invasion </plain></SENT>
<SENT sid="6" pm="."><plain>Adding NP1 to the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell line HT29 caused arrest at G1/S </plain></SENT>
<SENT sid="7" pm="."><plain>Treating HT29 cells with NP1 significantly decreased the expression of cyclin D1 and phosphorylation levels of Src, the adaptor protein Shc, and Erks </plain></SENT>
<SENT sid="8" pm="."><plain>The reduced level of cyclin D1 led to an increase in the activated form of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor <z:hpo ids='HP_0009919'>retinoblastoma</z:hpo> protein via dephosphorylation </plain></SENT>
<SENT sid="9" pm="."><plain>These actions led to attenuation of <z:mp ids='MP_0002006'>tumorigenesis</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Therefore, PLSCR1 may serve as a potential therapeutic target for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>